Wire · opportunities
FDA staff flags concerns for Capricor's Duchenne heart disease therapy
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 July 2026 · Fusion42 review
FDA staff raised concerns about whether Capricor's deramiocel cell therapy has sufficient evidence of effectiveness for treating cardiomyopathy in Duchenne muscular dystrophy patients, according to briefing documents released ahead of an advisory committee meeting.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
If you're building cell therapy for rare muscle disease, the FDA has just signalled that proven benefit in a handful of patients won't be enough—you need reproducible, measurable efficacy data. Capricor's struggle here maps the bar you'll need to clear.
◆ Coverage
1 source · 27 Jul 2026
◆ Related on Wire
◆ Topics